Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
When is a “Journal” … not a Journal?
By Dr. David Edward Marcinko; MBA, CMP™
Publisher-in-Chief
Allow me to begin this post by making the unusual disclosure that I was the Editor-in-Chief of a print guide in healthcare finance and economics [aka periodical or journal].
Formally, the title was: Healthcare Organizations [Financial Management Strategies]. At 2 volumes, and more than 1,200 pages, it was quite a job to update it quarterly. And, with more than two dozen contributing authors, it was a labor of love indeed. Alas … no more!
Varying Levels of Credibility
Now, we doctors know that medical journals are not all alike. There are different levels of “credibility.” Some are peer-reviewed, others not. Some are trade magazines. Frankly, some “real” journals are better, and more respected than others. Some entrenched journals are in decline, while other emerging journals are leading-edge in the health 2.0 space. Still others, like the formerly esteemed Journal of the American Medical Association [JAMA], have been accused of outright censorship.
Link: https://healthcarefinancials.wordpress.com/2009/04/02/is-jama-censoring-physician-dissent/
Adventures
Of course, doctors also know that pharmaceutical companies routinely offer us reprints of articles from medical journals that are favorable to their products. But, news of a Merck-sponsored publication for doctors in Australia has come to light in a personal injury lawsuit over Vioxx. It raised more than a few eyebrows in international medical publishing circles. It may have even crossed the line of journalistic, not to mention medical, ethics.
Read: Merck Paid for Medical ‘Journal’ Without Disclosure; by Natasha Singer, May 13, 2009.
Mis-Adverntures
Tracy Staton wrote more about these mis-adventures in a story, dated May 14, 2009, in FiercePharma.
Analysis and Apology
Analysis in the Pipeline: http://seekingalpha.com/article/136942-merck-and-elsevier-cross-the-line-in-joint-medical-journal?source=yahoo
Libology Mea Culpa: http://www.libology.com/blog/tag/excerpta-medica
Assessment
Perhaps; Merck ought to read our Medical-Executive Post on health journalists?
Link: https://healthcarefinancials.wordpress.com/2009/03/17/battered-health-journalists
Or, our Medical-Executive Post on medical experts, reporters and journalists?
Link: https://healthcarefinancials.wordpress.com/2009/03/09/healthcare-experts-versus-health-journalists
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
Share this:
Filed under: "Doctors Only", Breaking News, Career Development, Drugs and Pharma, Ethics, Health Economics, Health Insurance, Health Law & Policy, Healthcare Finance, iMBA, Inc., Op-Editorials, Recommended Books, Risk Management | Tagged: big-pharma, david marcinko, Drugs, JAMA, medical journals, Merck, Natasha Singer, pharmaceticals, Tracy Staton, Vioxx, www.healthcarefinancials.com |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Dr. Marcinko,
Industry Conflicts Common in Cancer Studies
Did you know that according to Kevin B. O’Reilly, of the AMNews on May 25, 2009, medical journal articles published by authors with financial conflicts are more likely to have positive outcomes. Yes, it is true says a new study by Reshma Jagsi, MD, PhD. Doctor Jagsi is the study’s lead author and assistant professor of radiation oncology at the University of Michigan Medical School.
Link: http://www.ama-assn.org/amednews/2009/05/25/prsa0525.htm
Nearly a third of oncology studies published in influential journals are authored by researchers with financial conflicts of interest, according to the May 11 study published online by the journal Cancer.
And so, unfortunately your criticisms seems increasingly true.
Dr. Gupta Singh
LikeLike
ME-P Subscribers,
You may read more on drug companies and health journalists, at this lnk:.
http://www.kevinmd.com/blog/2009/07/are-drug-companies-trying-to-influence-health-journalists.html
Samantha
LikeLike
ME-P Subscribers,
Did you know that up to 10 percent of the articles in the most prestigious medical journals were written by unacknowledged, industry-funded ghostwriters?
Yep! That’s the conclusion of a new study released by the editors of The Journal of the American Medical Association [JAMA]; as seen in this NYT article.
http://www.nytimes.com/2009/09/11/business/11ghost.html?_r=1&ref=health
Ann
Ann Miller; RN, MHA
[Executive Director]
LikeLike
Drug Company Used Ghostwriters for Works Bylined by Academics?
Newly released documents show how medical ghostwriters, paid for by a UK drug company, penned material published in medical journals and even a textbook.
Now, can you guess which UK drug company it was?
http://www.propublica.org/blog/item/drug-company-used-ghostwriters-to-write-work-bylined-by-academics-documents
So, what-up with the faux writers?
http://www.healthjournalism.org/blog/2010/11/ghostwritten-textbook-just-tip-of-the-iceberg/
Chester
LikeLike
The Bias of “Free” Medical Journals
It seems to be getting more and more difficult for physicians to gain access to unbiased information about the medications they prescribe–especially when that information is provided for free.
http://www.fiercepracticemanagement.com/story/study-free-journals-influenced-ads/2011-03-02?utm_medium=nl&utm_source=internal
So, does this mean they are actually very expensive?
Karen
LikeLike
Dr. Marcinko – Last week, a U.S. Senate committee launched an investigation into reports that doctors with financial ties to Medtronic were aware of serious complications with the product yet failed to reveal those problems in medical journal articles.
And, now the reports that led to the investigation have been published.
http://www.jsonline.com/watchdog/watchdogreports/124676453.html
Is this another faux journal in-the-making?
Andy
LikeLike
More on Peer Review
A few weeks back, the LSE Impact blog had a piece by Jason Priem on the use of twitter by academics that suggested peer review journals might become a thing of the past.
Then, our colleague Austin Frakt PhD wrote a brief post noting that as much as we love twitter, the role of peer review journals cannot be replaced by twitter, blogs or anything else (and we really believe in blogs!). We need the slow deliberative process that emphasizes trying to get it right, as opposed to doing it quickly.
We absolutely need the slow, peer review system as the foundation of thoughtful, careful scholarship. Twitter and other social media are important additions that can give scholarly content “reach” and “relevancy”. However, it’s a both/and, not an either/or proposition.
Traditional peer review journals should remain the bedrock of the research evidence that can be brought to bear on health policy.
http://theincidentaleconomist.com/wordpress/a-few-suggestions-on-peer-review/
At the ME-P, we agree with Austin. How about you?
Dr. David Edward Marcinko MBA CMP™
[Editor-in-Chief]
LikeLike
Heart researcher falsified red wine study, officials say
A University of Connecticut researcher known for his work on red wine’s benefits to cardiovascular health falsified his data in more than 100 instances, and nearly a dozen scientific journals are being warned of the potential problems after publishing his studies in recent years.
http://www.msnbc.msn.com/id/45959905/ns/health-health_care/
But, it’s not immediately clear whether the issues with the research would alter study conclusions.
Ann Miller RN MHA
LikeLike
Corruption of the medical literature is impossible to prevent
http://www.kevinmd.com/blog/2012/05/corruption-medical-literature-impossible-prevent.html
Or, is it?
Selma
LikeLike
Predatory Publishing?
According to Dina McKelvy [health science librarian], Jeffrey Beall is a research librarian at the University of Colorado at Denver who has undertaken a critical analysis of open access journal publishing, and maintains a list of publishers he believes are predatory.
Journal titles in a discipline may have very similar titles, and with the publishing world growing so rapidly, clinicians can be easily confused. His article, published in Nature, provides a checklist to help authors watch for predators: look closely at author fees, read sample articles, and contact members of the editorial board. Approach the process with healthy skepticism and common sense.
http://scholarlyoa.com/publishers/
Health science librarians are aware of the new landscape of open access. Include them in your publishing process – they can research and explain details such as the journal’s impact factor, and help you investigate a publisher.
Professor Hope Rachel Hetico RN MHA
http://www.BusinessofMedicalPractice.com
LikeLike
How journals are damaging science
A thoughtful and provocative piece over at the “Guardian” via the “Incidental Economist.”
I am a scientist. Mine is a professional world that achieves great things for humanity. But it is disfigured by inappropriate incentives. The prevailing structures of personal reputation and career advancement mean the biggest rewards often follow the flashiest work, not the best. Those of us who follow these incentives are being entirely rational – I have followed them myself – but we do not always best serve our profession’s interests, let alone those of humanity and society.
We all know what distorting incentives have done to finance and banking. The incentives my colleagues face are not huge bonuses, but the professional rewards that accompany publication in prestigious journals – chiefly Nature, Cell and Science.
http://theincidentaleconomist.com/wordpress/how-journals-are-damaging-science/
Go read the whole thing. Totally worth your time. We are having a hard time disagreeing with the piece.
Hope R. Hetico RN MHA
LikeLike
BEWARE
https://www.msn.com/en-us/news/us/the-pandemic-claims-new-victims-prestigious-medical-journals/ar-BB15tC3I?li=BBnb7Kz
Dr. David E. Marcinko MBA
LikeLike